IceCure Medical Ltd. (ICCM) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and thank you for standing by. Currently, all of the participants are in listen-only mode. After management's discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference over to Michael Polyview. Please go ahead. Thank you, Hila, and welcome to Iceture Medical's conference call to review the initial results as of and for the 12-month end of December 31, 2025, and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning. Participating on today's call is iCertio Medical CEO, Eyal Shamir. The company's CP Sales North America, Shadgood, is not able to join due to connectivity issues, so I will read his prepared statement. Jay LeVay, the company's COO, will be available during the Q&A portion of the call. Before we begin, I'll now take a moment to read a statement about federal liquor statements. The call and the question and answer section follows the contained federal liquor statements within the meaning of the safe harbor provisions of the private securities litigation and reform act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates, and similar expressions or variations of such words are intended to identify federal liquor statements. For example, we are using statements in this presentation when we discuss the FDA's marketing authorization for post-sense will drive meaningful growth for us. The post-marketing study for post-sense growth in the interest installation of post-sense systems in a hospital potential increases interest for post-sense from breast radiologists and surgeons. The follow-up statements c...